We identified two (2) new or newly emerging biotech companies for December 2024. To find these new/emerging bio/pharma companies, every workday, our team uses a combination of automated and manual systems to search numerous online resources and adds these new/emerging companies to our online biopharmIQ platform. The 2 new/emerging companies from December focus on small molecule pharmaceutical development and gene therapy, respectively, with both headquartered in Boston, Massachusetts (FIG 1).
FIG. 1. New/newly emerging companies in December 2024.
Tasca Therapeutics
Focus: Small molecule inhibitors using mass spectrometry-based proteomics
Location: Boston, Massachusetts, United States
Insight: Tasca uses mass spectrometry-based proteomics to identify cancer-driving proteins that undergo auto-palmitoylation and develops small-molecule inhibitors to block their function.
nChroma Bio
Focus: Epigenetic editing therapy and non-viral programmable delivery
Location: Boston & Cambridge, Massachusetts, United States
Insight: Emerged from Chroma Medicine and Nvelop Therapeutics merger; nChroma Bio focuses on epigenetic editing and non-viral in vivo delivery, leveraging the body’s natural gene-regulation mechanisms instead of traditional DNA-cutting approaches.
These new/emerging companies in December 2024 appear to be exciting new additions to Boston’s biotech hotbed community.
Want to get notified any time a new/emerging company forms, or any time a company with your target attributes gets funded? Sign up for our Free Notification Service.
Have questions or want to schedule an online demo?
Contact marketing@biopharmIQ.com.
***
Article History:
RF/MV/JD/DG (01/06/25)
Not legal, investing, or tax advice.
Kommentarer